Skip to Content

Fidelity Advisor Biotechnology A FBTAX

Medalist Rating as of | See Fidelity Investment Hub
  • NAV / 1-Day Return 31.48  /  +3.52 %
  • Total Assets 1.7 Bil
  • Adj. Expense Ratio
    1.010%
  • Expense Ratio 1.010%
  • Distribution Fee Level Low
  • Share Class Type Front Load
  • Category Health
  • Investment Style Mid Blend
  • Min. Initial Investment
  • Status Open
  • TTM Yield 1.11%
  • Turnover 78%

USD | NAV as of Feb 27, 2024 | 1-Day Return as of Feb 27, 2024, 11:13 PM GMT+0

Morningstar’s Analysis FBTAX

Will FBTAX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Fidelity Advisor Biotechnology A’s Process Pillar rating is Average, but a strong management team still helps this strategy retain its Morningstar Medalist Rating of Bronze.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The strategy charges fees in line with its similarly distributed peers, priced within the middle quintile.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings FBTAX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 65.5
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

AbbVie Inc

23.22 376.5 Mil
Healthcare

Amgen Inc

11.13 180.5 Mil
Healthcare

Regeneron Pharmaceuticals Inc

8.73 141.5 Mil
Healthcare

Cytokinetics Inc

4.33 70.2 Mil
Healthcare

Alnylam Pharmaceuticals Inc

4.04 65.6 Mil
Healthcare

Ascendis Pharma A/S ADR

3.93 63.7 Mil
Healthcare

Gilead Sciences Inc

3.71 60.2 Mil
Healthcare

argenx SE ADR

2.46 39.9 Mil
Healthcare

Vaxcyte Inc Ordinary Shares

2.32 37.6 Mil
Healthcare

Vertex Pharmaceuticals Inc

1.67 27.1 Mil
Healthcare